Ovid Therapeutics
OVID
79 hedge funds and large institutions have $161M invested in Ovid Therapeutics in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 17 closing their positions.
240% more capital invested
Capital invested by funds: $47.3M → $161M (+$114M)
129% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 17
77% more call options, than puts
Call options by funds: $768K | Put options by funds: $434K
39% more funds holding
Funds holding: 57 → 79 (+22)
10.89% more ownership
Funds ownership: 29.02% → 39.91% (+11%)
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.3M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.17M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.44M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$3.16M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.42M |
| 2 |
CA
CHI Advisors
New York
|
-$1.33M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.13M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.1M |
| 5 |
Renaissance Technologies
New York
|
-$1.07M |
OVID Hedge Fund Activity: Q2 2020 in Review
79 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2020, worth a combined $161M — up 240% from $47.3M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new OVID positions and 17 closed out — a net gain of 22 holders — while 18 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $11.3M. The largest seller was Fidelity Investments, cutting an estimated $1.42M.
- 79 institutional investors held Ovid Therapeutics (OVID) as of Q2 2020, up from 57 in Q1 2020.
- Funds reported $161M of Ovid Therapeutics stock for Q2 2020, up 240% quarter-over-quarter.
- 39 funds opened new Ovid Therapeutics positions in Q2 2020 and 17 closed out, a net change of +22 holders.
- The largest Ovid Therapeutics buyer in Q2 2020 was BlackRock, an estimated $11.3M added.
- The largest Ovid Therapeutics seller in Q2 2020 was Fidelity Investments, an estimated $1.42M sold.
Based on aggregated 13F filings for Q2 2020.